1
|
Valenti A, Falcone I, Valenti F, Ricciardi E, Di Martino S, Maccallini MT, Cerro M, Desiderio F, Miseo L, Russillo M, Guerrisi A. Biobanks as an Indispensable Tool in the "Era" of Precision Medicine: Key Role in the Management of Complex Diseases, Such as Melanoma. J Pers Med 2024; 14:731. [PMID: 39063985 PMCID: PMC11278009 DOI: 10.3390/jpm14070731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2024] [Revised: 07/02/2024] [Accepted: 07/03/2024] [Indexed: 07/28/2024] Open
Abstract
In recent years, medicine has undergone profound changes, strongly entering a new phase defined as the "era of precision medicine". In this context, patient clinical management involves various scientific approaches that allow for a comprehensive pathology evaluation: from preventive processes (where applicable) to genetic and diagnostic studies. In this scenario, biobanks play an important role and, over the years, have gained increasing prestige, moving from small deposits to large collections of samples of various natures. Disease-oriented biobanks are rapidly developing as they provide useful information for the management of complex diseases, such as melanoma. Indeed, melanoma, given its highly heterogeneous characteristics, is one of the oncologic diseases with the greatest clinical and therapeutic management complexity. So, the possibility of extrapolating tissue, genetic and imaging data from dedicated biobanks could result in more selective study approaches. In this review, we specifically analyze the several biobank types to evaluate their role in technology development, patient monitoring and research of new biomarkers, especially in the melanoma context.
Collapse
Affiliation(s)
- Alessandro Valenti
- Radiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy; (F.D.); (L.M.); (A.G.)
| | - Italia Falcone
- SAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy;
| | - Fabio Valenti
- UOC Oncological Translational Research, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy; (F.V.); (E.R.)
| | - Elena Ricciardi
- UOC Oncological Translational Research, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy; (F.V.); (E.R.)
| | - Simona Di Martino
- UOC Pathology Unit, Biobank IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy;
| | - Maria Teresa Maccallini
- Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, 00185 Rome, Italy; (M.T.M.); (M.C.)
| | - Marianna Cerro
- Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, 00185 Rome, Italy; (M.T.M.); (M.C.)
| | - Flora Desiderio
- Radiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy; (F.D.); (L.M.); (A.G.)
| | - Ludovica Miseo
- Radiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy; (F.D.); (L.M.); (A.G.)
| | - Michelangelo Russillo
- Division of Medical Oncology, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy;
| | - Antonino Guerrisi
- Radiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy; (F.D.); (L.M.); (A.G.)
| |
Collapse
|
2
|
Rodriguez Llorian E, Kopac N, Waliji LA, Borle K, Dragojlovic N, Elliott AM, Lynd LD. A Rapid Review on the Value of Biobanks Containing Genetic Information. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2023; 26:1286-1295. [PMID: 36921900 DOI: 10.1016/j.jval.2023.02.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Revised: 01/20/2023] [Accepted: 02/24/2023] [Indexed: 06/18/2023]
Abstract
OBJECTIVES Increasing access to health data through biobanks containing genetic information has the potential to expand the knowledge base and thereby improve screening, diagnosis, and treatment options for many diseases. Nevertheless, although privacy concerns and risks surrounding genetic data sharing are well documented, direct evidence in favor of the hypothesized benefits of data integration is scarce, which complicates decision making in this area. Therefore, the objective of this study is to summarize the available evidence on the research and clinical impacts of biobanks containing genetic information, so as to better understand how to quantify the value of expanding genomic data access. METHODS Using a rapid review methodology, we performed a search of MEDLINE/PubMed and Embase databases; and websites of biobanks and genomic initiatives published from 2010 to 2022. We classified findings into 11 indicators including outputs (a direct product of the biobank activities) and outcomes (changes in scientific and clinical capacity). RESULTS Of 8479 abstracts and 101 gray literature sources were reviewed, 96 records were included. Although most records did not report key indicators systematically, the available evidence concentrated on research indicators such as publications and gene-disorder association discoveries (63% of studies), followed by research infrastructure (26%), and clinical indicators (11%) such as supporting the diagnosis of individual patients. CONCLUSIONS Existing evidence on the benefits of biobanks is skewed toward easily quantifiable research outputs. Measuring a comprehensive set of outputs and outcomes inspired by value frameworks is necessary to generate better evidence on the benefits of genomic data sharing.
Collapse
Affiliation(s)
- Elisabet Rodriguez Llorian
- Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
| | - Nicola Kopac
- Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Louloua Ashikhusein Waliji
- Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Kennedy Borle
- Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Nick Dragojlovic
- Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Alison M Elliott
- Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Larry D Lynd
- Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada; Centre for Health Evaluation and Outcome Sciences (CHÉOS), St. Paul's Hospital, Vancouver, BC, Canada
| |
Collapse
|
3
|
LaLonde-Paul D, Mouttham L, Promislow DEL, Castelhano MG. Banking on a new understanding: translational opportunities from veterinary biobanks. GeroScience 2023:10.1007/s11357-023-00763-z. [PMID: 36890420 PMCID: PMC10400517 DOI: 10.1007/s11357-023-00763-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Accepted: 01/03/2023] [Indexed: 03/10/2023] Open
Abstract
Current advances in geroscience are due in part to the discovery of biomarkers with high predictive ability in short-lived laboratory animals such as flies and mice. These model species, however, do not always adequately reflect human physiology and disease, highlighting the need for a more comprehensive and relevant model of human aging. Domestic dogs offer a solution to this obstacle, as they share many aspects not only of the physiological and pathological trajectories of their human counterpart, but also of their environment. Furthermore, they age at a considerably faster rate. Studying aging in the companion dog provides an opportunity to better understand the biological and environmental determinants of healthy lifespan in our pets, and to translate those findings to human aging. Biobanking, the systematic collection, processing, storage, and distribution of biological material and associated data has contributed to basic, clinical, and translational research by streamlining the management of high-quality biospecimens for biomarker discovery and validation. In this review, we discuss how veterinary biobanks can support research on aging, particularly when integrated into large-scale longitudinal studies. As an example of this concept, we introduce the Dog Aging Project Biobank.
Collapse
Affiliation(s)
- D LaLonde-Paul
- Cornell Veterinary Biobank, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| | - L Mouttham
- Cornell Veterinary Biobank, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| | | | - D E L Promislow
- Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA
- Department of Biology, University of Washington, Seattle, WA, USA
| | - M G Castelhano
- Cornell Veterinary Biobank, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
| |
Collapse
|
4
|
Gao B, Shu Z, Ren S, Gao D. Biobanking: A foundation of life-science research and advancement. BIOSAFETY AND HEALTH 2022. [DOI: 10.1016/j.bsheal.2022.09.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
5
|
Tarling TE, Byrne JA, Watson PH. The Availability of Human Biospecimens to Support Biomarker Research. Biomark Insights 2022; 17:11772719221091750. [PMID: 35464611 PMCID: PMC9021506 DOI: 10.1177/11772719221091750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 03/15/2022] [Indexed: 11/16/2022] Open
Abstract
Preserved biospecimens held in biobank inventories and clinical archives are important resources for biomarker research. Recent advances in technologies have led to an increase in use of clinical archives in particular, in order to study retrospective cohorts and to generate data relevant to tissue biomarkers. This raises the question of whether the current sizes of biobank inventories are appropriate to meet the demands of biomarker research. This commentary discusses this question by considering data concerning overall biobank and biospecimen numbers to estimate current biospecimen supply and use. The data suggests that biospecimen supply exceeds current demand. Therefore, it may be important for individual biobanks to reassess the targets for their inventories, consider culling unused portions of these inventories, and shift resources towards providing prospective custom biobanking services.
Collapse
Affiliation(s)
- Tamsin E Tarling
- Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, BC, Canada.,Canadian Tissue Repository Network, Vancouver, Canada
| | - Jennifer A Byrne
- New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, NSW, Australia.,School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
| | - Peter H Watson
- Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, BC, Canada.,Canadian Tissue Repository Network, Vancouver, Canada
| |
Collapse
|
6
|
Kanakoglou DS, Pampalou A, Vrachnos DM, Karatrasoglou EA, Zouki DN, Dimonitsas E, Klonou A, Kokla G, Theologi V, Christofidou E, Sakellariou S, Lakiotaki E, Piperi C, Korkolopoulou P. Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer. Int J Oncol 2022; 60:31. [PMID: 35169862 PMCID: PMC8878762 DOI: 10.3892/ijo.2022.5321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2021] [Accepted: 12/23/2021] [Indexed: 11/06/2022] Open
Abstract
Biobanks constitute an integral part of precision medicine. They provide a repository of biospecimens that may be used to elucidate the pathophysiology, support diagnoses, and guide the treatment of diseases. The pilot biobank of rare malignant neoplasms has been established in the context of the Hellenic Network of Precision Medicine on Cancer and aims to enhance future clinical and/or research studies in Greece by collecting, processing, and storing rare malignant neoplasm samples with associated data. The biobank currently comprises 553 samples; 384 samples of hematopoietic and lymphoid tissue malignancies, 72 samples of pediatric brain tumors and 97 samples of malignant skin neoplasms. In this article, sample collections and their individual significance in clinical research are described in detail along with computational methods developed specifically for this project. A concise review of the Greek biobanking landscape is also delineated, in addition to recommended technologies, methodologies and protocols that were integrated during the creation of the biobank. This project is expected to re‑enforce current clinical and research studies, introduce advances in clinical and genetic research and potentially aid in future targeted drug discovery. It is our belief that the future of medical research is entwined with accessible, effective, and ethical biobanking and that our project will facilitate research planning in the '‑omic' era by contributing high‑quality samples along with their associated data.
Collapse
Affiliation(s)
- Dimitrios S. Kanakoglou
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Andromachi Pampalou
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Dimitrios M. Vrachnos
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Eleni A. Karatrasoglou
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Dionysia N. Zouki
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Emmanouil Dimonitsas
- Department of Plastic and Reconstructive Surgery, Greek Anticancer Institute, Saint Savvas Hospital, 11522 Athens, Greece
| | - Alexia Klonou
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Georgia Kokla
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Varvara Theologi
- Department of Pathology, Andreas Syggros Hospital of Cutaneous and Venereal Diseases, 16121 Athens, Greece
| | - Errieta Christofidou
- Department of Pathology, Andreas Syggros Hospital of Cutaneous and Venereal Diseases, 16121 Athens, Greece
| | - Stratigoula Sakellariou
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Eleftheria Lakiotaki
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Christina Piperi
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Penelope Korkolopoulou
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| |
Collapse
|
7
|
Rush A, Catchpoole DR, Reaiche-Miller G, Gilbert T, Ng W, Watson PH, Byrne JA. What Do Biomedical Researchers Want from Biobanks? Results of an Online Survey. Biopreserv Biobank 2021; 20:271-282. [PMID: 34756100 DOI: 10.1089/bio.2021.0084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Aims: The purpose of biobanking is to provide biospecimens and associated data to researchers, yet the perspectives of biobank research users have been under-investigated. This study aimed to ascertain biobank research users' needs and opinions about biobanking services. Methods: An online survey was developed, which requested information about researcher demographics, localities of biobanks accessed, methods of sourcing biospecimens, and opinions on topics including but not limited to, application processes, data availability, access fees, and return of research results. There were 27 multiple choice/check box questions, 4 questions with a 10-point Likert scale, and 8 questions with provision for further comment. A web link for the survey was distributed to researchers in late 2019/early 2020 in four Australian states: New South Wales, Victoria, Western Australia, and South Australia. Results: Respondents were generally satisfied with biobank application processes and the fit for purpose of received biospecimens/data. Nonetheless, most researchers (n = 61/99, 62%) reported creating their own collections owing to gaps in sample availability and a perceived increase in efficiency. Most accessed biobanks (n = 58/74, 78%) were in close proximity (local or intrastate) to the researcher. Most researchers had limited the scope of their research owing to difficulty of obtaining biospecimens (n = 55/86, 64%) and/or data (n = 52/85, 60%), with the top three responses for additional types of data required being "more long term follow up data," "more clinical data," and "more linked government data." The top influence to use a particular biobank was cost, and the most frequently suggested improvement was reduced direct "cost of obtaining biospecimens." Conclusion: Biobanks that do not meet the needs of their end-users are unlikely to be optimally utilized or sustainable. This survey provides valuable insights to guide biobanks and other stakeholders, such as developing marketing and client engagement plans to encourage local research users and discouraging the creation of unnecessary new collections.
Collapse
Affiliation(s)
- Amanda Rush
- New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, Australia
| | - Daniel R Catchpoole
- Children's Cancer Research Unit, Kids Research, The Children's Hospital at Westmead, Westmead, Australia
| | - Georget Reaiche-Miller
- Division of Research and Innovation, The University of Adelaide Biobank, Adelaide, Australia
| | - Thomas Gilbert
- The University of Western Australia Medical School, University of Western Australia, Perth, Australia
| | - Wayne Ng
- Victorian Cancer Biobank, Melbourne, Australia
| | - Peter Hamilton Watson
- Biobanking and Biospecimen Research Services, British Columbia Cancer, Victoria, Canada
- Canadian Tissue Repository Network, British Columbia Cancer, Vancouver, Canada
| | - Jennifer A Byrne
- New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, Australia
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| |
Collapse
|
8
|
Annaratone L, De Palma G, Bonizzi G, Sapino A, Botti G, Berrino E, Mannelli C, Arcella P, Di Martino S, Steffan A, Daidone MG, Canzonieri V, Parodi B, Paradiso AV, Barberis M, Marchiò C. Basic principles of biobanking: from biological samples to precision medicine for patients. Virchows Arch 2021; 479:233-246. [PMID: 34255145 PMCID: PMC8275637 DOI: 10.1007/s00428-021-03151-0] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2021] [Revised: 06/24/2021] [Accepted: 06/30/2021] [Indexed: 12/15/2022]
Abstract
The term "biobanking" is often misapplied to any collection of human biological materials (biospecimens) regardless of requirements related to ethical and legal issues or the standardization of different processes involved in tissue collection. A proper definition of biobanks is large collections of biospecimens linked to relevant personal and health information (health records, family history, lifestyle, genetic information) that are held predominantly for use in health and medical research. In addition, the International Organization for Standardization, in illustrating the requirements for biobanking (ISO 20387:2018), stresses the concept of biobanks being legal entities driving the process of acquisition and storage together with some or all of the activities related to collection, preparation, preservation, testing, analysing and distributing defined biological material as well as related information and data. In this review article, we aim to discuss the basic principles of biobanking, spanning from definitions to classification systems, standardization processes and documents, sustainability and ethical and legal requirements. We also deal with emerging specimens that are currently being generated and shaping the so-called next-generation biobanking, and we provide pragmatic examples of cancer-associated biobanking by discussing the process behind the construction of a biobank and the infrastructures supporting the implementation of biobanking in scientific research.
Collapse
Affiliation(s)
- Laura Annaratone
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.,Department of Medical Sciences, University of Turin, Turin, Italy
| | - Giuseppe De Palma
- Institutional BioBank, Experimental Oncology and Biobank Management Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - Giuseppina Bonizzi
- Unit of Histopathology and Molecular Diagnostics, Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - Anna Sapino
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.,Department of Medical Sciences, University of Turin, Turin, Italy
| | - Gerardo Botti
- Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy
| | - Enrico Berrino
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.,Department of Medical Sciences, University of Turin, Turin, Italy
| | | | - Pamela Arcella
- Department of Oncology, University of Turin, Turin, Italy
| | - Simona Di Martino
- Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Agostino Steffan
- Immunopathology and Cancer Biomarkers, IRCCS CRO Aviano-National Cancer Institute, Aviano, Italy
| | | | - Vincenzo Canzonieri
- Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.,Pathology Unit, IRCCS CRO Aviano-National Cancer Institute, Aviano, Italy
| | | | - Angelo Virgilio Paradiso
- Institutional BioBank, Experimental Oncology and Biobank Management Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - Massimo Barberis
- Unit of Histopathology and Molecular Diagnostics, Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - Caterina Marchiò
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. .,Department of Medical Sciences, University of Turin, Turin, Italy.
| | | |
Collapse
|
9
|
Neuber AC, Tostes CH, Ribeiro AG, Marczynski GT, Komoto TT, Rogeri CD, da Silva VD, Mauad EC, Reis RM, Marques MMC. The biobank of barretos cancer hospital: 14 years of experience in cancer research. Cell Tissue Bank 2021; 23:271-284. [PMID: 34216325 DOI: 10.1007/s10561-021-09941-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 06/20/2021] [Indexed: 01/15/2023]
Abstract
Despite the developments in cancer research over years, cancer is still one of the leading causes of death worldwide. In Brazil, the number of cancer cases for the several next years (2020-2022) is expected to increase up to 625,000. Thus, translational research has been vital to determine the potential risk, prognostic, and predictive biomarkers in cancer. Therefore, Barretos Cancer Hospital implemented a biobank (BB-BCH) in 2006, which is responsible for processing, storage, and provision of biological materials from cancer and non-cancer participants. Hence, this article aimed to describe BB-BCH's history, experiences, and outcomes and explore its impact on Brazilian translational oncology research scenario. BB-BCH has a multidisciplinary team who are responsible for guaranteeing the quality of all processes as recommended by international guidelines for biobanks. Furthermore, BB-BCH has ample equipment to ensure the quality of all material requested by researchers as genetic material (DNA and RNA) and/or entire biospecimens. From 2006 to 2019, BB-BCH contained 252,069 samples from 44,933 participants, the whole collection is represented by 15 different types of biospecimens collected from them. According to our data, the most collected and stored topography in men is head and neck (29%); in women is breast (28%); and in children is torso and limb (27%) samples. Finally, we supported national and international consortia and projects such as The Cancer Genome Atlas. BB-BCH is a vital knowledge source for scientific community, enabling the development of high-quality studies, with a wide variety of tumor categories and high national representativeness of Brazilian population.
Collapse
Affiliation(s)
| | | | - Adeylson Guimarães Ribeiro
- Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Vilela, 1331, 14784-400, Barretos, SP, Brazil
| | | | | | | | - Vinicius Duval da Silva
- Barretos Cancer Hospital Biobank, São Paulo, Brazil.,Department of Pathology, Barretos Cancer Hospital, São Paulo, Brazil
| | - Edmundo Carvalho Mauad
- Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Vilela, 1331, 14784-400, Barretos, SP, Brazil
| | - Rui Manuel Reis
- Barretos Cancer Hospital Biobank, São Paulo, Brazil.,Department of Prevention, Barretos Cancer Hospital, Barretos, Brazil.,Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.,ICVS/3B's-PT Government Associate Laboratory, Braga, Portugal
| | - Márcia M C Marques
- Barretos Cancer Hospital Biobank, São Paulo, Brazil. .,Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Vilela, 1331, 14784-400, Barretos, SP, Brazil. .,Barretos School of Health Sciences, Barretos, SP, Brazil.
| |
Collapse
|
10
|
Byrne JA, Carpenter JE, Carter C, Phillips K, Braye S, Watson PH, Rush A. Building Research Support Capacity across Human Health Biobanks during the COVID-19 Pandemic. Biomark Insights 2021; 16:11772719211024100. [PMID: 34177256 PMCID: PMC8207259 DOI: 10.1177/11772719211024100] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 05/12/2021] [Indexed: 11/23/2022] Open
Abstract
Human health biobanks are forms of research infrastructure that supply biospecimens and associated data to researchers, and therefore juxtapose the activities of clinical care and biomedical research. The discipline of biobanking has existed for over 20 years and is supported by several international professional societies and dedicated academic journals. However, despite both rising research demand for human biospecimens, and the growth of biobanking as an academic discipline, many individual biobanks continue to experience sustainability challenges. This commentary will summarize how the COVID-19 pandemic is creating new challenges and opportunities for both the health biobanking sector and the supporting discipline of biobanking. While the challenges for biobanks may be numerous and acute, there are opportunities for both individual biobanks and the discipline of biobanking to embrace change such that biobanks can continue to support and drive biomedical research. We will therefore describe numerous practical steps that individual biobanks and/or the discipline of biobanking can take to survive and possibly thrive in response to the COVID-19 pandemic.
Collapse
Affiliation(s)
- Jennifer A Byrne
- New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, NSW, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
| | - Jane E Carpenter
- New South Wales Health Pathology, Newcastle, NSW, Australia.,Scientific Platforms, The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia
| | - Candace Carter
- New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, NSW, Australia
| | - Kathleen Phillips
- New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, NSW, Australia
| | - Stephen Braye
- New South Wales Health Pathology, Newcastle, NSW, Australia
| | - Peter H Watson
- Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer Agency, Victoria, BC, Canada.,Canadian Tissue Repository Network, Vancouver, BC, Canada
| | - Amanda Rush
- New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, NSW, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.,Children's Cancer Research Unit, Kids Research, The Children's Hospital at Westmead, Westmead, NSW, Australia
| |
Collapse
|
11
|
Rush A, Catchpoole DR, Ling R, Searles A, Watson PH, Byrne JA. Improving Academic Biobank Value and Sustainability Through an Outputs Focus. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2020; 23:1072-1078. [PMID: 32828220 DOI: 10.1016/j.jval.2020.05.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 05/18/2020] [Accepted: 05/23/2020] [Indexed: 06/11/2023]
Abstract
Although it is generally accepted that human tissue biobanks are important to facilitate progress in health and medical research, many academic biobanks face sustainability challenges. We propose that biobank sustainability is challenged by a lack of available data describing the outputs and benefits that are produced by biobanks, as reflected by a dearth of publications that enumerate biobank outputs. We further propose that boosting the available information on biobank outputs and using a broader range of output metrics will permit economic analyses such as cost-consequence analyses of biobank activity. Output metrics and cost-consequence analyses can allow biobanks to achieve efficiencies, and improve the quality and/or quantity of their outputs. In turn, biobank output measures provide all stakeholders with explicit and accountable data on biobank value, which could contribute to the evolution of biobank operations to best match research needs, and mitigate some threats to biobank sustainability.
Collapse
Affiliation(s)
- Amanda Rush
- Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
| | - Daniel R Catchpoole
- Children's Cancer Research Unit, Kids Research, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Rod Ling
- Health Research Economics, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
| | - Andrew Searles
- Health Research Economics, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
| | - Peter H Watson
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - Jennifer A Byrne
- NSW Health Statewide Biobank, NSW Health Pathology, Professor Marie Bashir Centre, Camperdown, NSW, Australia.
| |
Collapse
|
12
|
Barnes RO, Watson PH. Precision medicine: Driving the evolution of biobanking quality. Healthc Manage Forum 2020; 33:102-106. [PMID: 31957497 DOI: 10.1177/0840470419898874] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The promise of precision medicine will only be realized if the healthcare system adapts to meet some key infrastructure needs. Among these needs are adequate biobanking practices, capable of producing the biological samples and data that precision medicine relies upon in both the research and clinical phases. Within the research domain, there have been significant improvements to biobanking processes over the past two decades, driven by increased understanding of the impact of pre-analytical variability and the critical role of biospecimen and data quality. In the era of precision medicine, biobanking to support clinical needs has similar quality requirements. The extensive knowledge and resources that have been developed by the research biobanking community are available for adoption by clinical biobanking. The challenge and opportunity now presented to the healthcare system is to adopt or adapt these resources, for example, external biobanking standards and verification programs.
Collapse
Affiliation(s)
- Rebecca O Barnes
- Research and Capacity Building, Vancouver Island Health Authority, Victoria, British Columbia, Canada.,Canadian Tissue Repository Network, Vancouver, British Columbia, Canada
| | - Peter H Watson
- Canadian Tissue Repository Network, Vancouver, British Columbia, Canada.,Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.,Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada
| |
Collapse
|
13
|
Watson PH, Hewitt RE, Catchpoole DR, Grizzle WE. Biobank: What's in a Name? Biopreserv Biobank 2019; 17:204-208. [PMID: 31188628 DOI: 10.1089/bio.2019.29053.mjb] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Affiliation(s)
- Peter H Watson
- 2 Biobanking and Biospecimen Research Services, British Columbia Cancer-Victoria Center and University of British Columbia, Deeley Research Centre, Victoria, Canada
| | | | - Daniel R Catchpoole
- 4 The Tumour Bank-CCRU, Kids Research, The Children's Hospital at Westmead, Westmead, Australia
| | - William E Grizzle
- 5 Division of Anatomic Pathology, Department of Pathology, The University of Alabama at Birmingham (UAB), Birmingham, Alabama
| |
Collapse
|
14
|
Hartman V, Gali B, Dee S, O'Donoghue S, Tarling T, Barnes R, de Ladurantaye M, Mes-Masson AM, Watson PH. Canadian Tissue Repository Network Biobank Certification Program: Update and Review of the Program from 2011 to 2018. Biopreserv Biobank 2019; 17:530-538. [PMID: 31194579 DOI: 10.1089/bio.2019.0015] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
The Canadian Tissue Repository Network (CTRNet) Biobank Certification Program was first launched in 2011 to foster translational research through improved access to high quality biospecimens. This was accomplished by creating and providing biobank education and through the establishment and deployment of common standards to harmonize biospecimen quality and approaches to governance. The CTRNet program comprises registration and certification steps as two linked phases. In the two-step registration phase, the biobank is registered into the system, and an individual completes an overview educational module. In the subsequent certification phase, biobanks undergo a seven-step process, including inviting team members, assigning and completing relevant education modules, uploading documents, and undergoing a documentation audit. As of June 2018, there were 251 biobanks engaged in the CTRNet program, 193 had completed registration, and 40 were fully certified. Over 3/4 of these biobanks completed registration within a week and over 1/3 completed certification within a month. Among registered biobanks, 163 were associated with North American institutions, while 30 were from other international locations, including Australia, Europe, and Asia. The CTRNet program enables biobanks to adopt standards with a flexible approach to accommodate different types of biobanks and a measured investment of effort, creating the foundation for increased access to high quality biospecimens.
Collapse
Affiliation(s)
- Victoria Hartman
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center, Victoria, Canada
| | - Brent Gali
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center, Victoria, Canada.,Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - Simon Dee
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center, Victoria, Canada.,Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.,Canadian Tissue Repository Network, Vancouver, Canada
| | - Sheila O'Donoghue
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center, Victoria, Canada.,Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.,Canadian Tissue Repository Network, Vancouver, Canada
| | - Tamsin Tarling
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center, Victoria, Canada.,Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | | | - Manon de Ladurantaye
- Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Institut du cancer de Montréal, Montreal, Canada
| | - Anne-Marie Mes-Masson
- Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Institut du cancer de Montréal, Montreal, Canada.,Department of Medicine, Université de Montréal, Montreal, Canada
| | - Peter H Watson
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center, Victoria, Canada.,Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.,Canadian Tissue Repository Network, Vancouver, Canada
| |
Collapse
|
15
|
Hartman V, Matzke L, Watson PH. Biospecimen Complexity and the Evolution of Biobanks. Biopreserv Biobank 2019; 17:264-270. [DOI: 10.1089/bio.2018.0120] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Victoria Hartman
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center and University of British Columbia, Victoria, Canada
| | - Lise Matzke
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center and University of British Columbia, Victoria, Canada
- Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research, University of British Columbia, Vancouver, Canada
| | - Peter H. Watson
- Biobanking and Biospecimen Research Services, Deeley Research Centre, British Columbia Cancer-Victoria Center and University of British Columbia, Victoria, Canada
- Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research, University of British Columbia, Vancouver, Canada
| |
Collapse
|
16
|
Rush A, Matzke L, Cooper S, Gedye C, Byrne JA, Watson PH. Research Perspective on Utilizing and Valuing Tumor Biobanks. Biopreserv Biobank 2019; 17:219-229. [DOI: 10.1089/bio.2018.0099] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Affiliation(s)
- Amanda Rush
- Children's Cancer Research Unit, Kids Research, The Children's Hospital at Westmead, Discipline of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Lise Matzke
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - Simon Cooper
- NSW Health Statewide Biobank, NSW Health Pathology, The Professor Marie Bashir Centre, Sydney, Australia
| | - Craig Gedye
- NSW Health Statewide Biobank, NSW Health Pathology, The Professor Marie Bashir Centre, Sydney, Australia
| | - Jennifer A. Byrne
- Children's Cancer Research Unit, Kids Research, The Children's Hospital at Westmead, Discipline of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Peter H. Watson
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- Biobanking and Biospecimen Research Services, BC Cancer Research Center, Vancouver, Canada
- Canadian Tissue Repository Network, Deeley Research Centre, British Columbia Cancer-Victoria Center and University of British Columbia, Victoria, Canada
| |
Collapse
|
17
|
Khabour OF, Abu-Siniyeh A. Challenges that face the establishment of diabetes biobank in Jordan: a qualitative analysis of an online discussion forum. J Multidiscip Healthc 2019; 12:229-234. [PMID: 31114216 PMCID: PMC6489903 DOI: 10.2147/jmdh.s194161] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Introduction: Diabetes is common in Jordan with a prevalence of about 13% of the population. Establishment of a diabetes biobank in Jordan could have an enormous impact on the management and prevention of the disease. Methods: In the current study, ethical challenges that might face the establishment of a biobank were examined by 28 researchers from the Middle East and North Africa region using an online discussion forum. Results: All participants agreed on the importance of the establishment of a diabetes biobank in Jordan. The possible challenges that were discussed included confidentiality and privacy, informed consent, specimen ownership and participants’ rights, data sharing, returning of research results and incidental findings, lack of legislations, and importance of social awareness and public engagements with biobanks. Conclusion: In conclusion, participants support the establishment of a diabetes biobank in Jordan; however, some ethical issues should be considered to ensure the success of the biobank.
Collapse
Affiliation(s)
- Omar F Khabour
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan
| | - Ahmed Abu-Siniyeh
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan.,Department of Medical Laboratory Sciences, Faculty of Science, Al-Balqa' Applied University, As Salt, Jordan.,Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia
| |
Collapse
|
18
|
Paradiso AV, Daidone MG, Canzonieri V, Zito A. Biobanks and scientists: supply and demand. J Transl Med 2018; 16:136. [PMID: 29783984 PMCID: PMC5963141 DOI: 10.1186/s12967-018-1505-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 05/05/2018] [Indexed: 02/07/2023] Open
Abstract
The biobanks, providers of biospecimens, and the scientists, users of biological material, are both strategic actors in translational medicine but the communication about those two subjects seems to be delicate. Recently, biobank managers from US and Europe stressed the danger of underuse of biospecimens stored in their biobanks thus stimulating the debate about innovative ways to collect samples and to communicate their availability. We hypothesize that the already stored collections meet the interest of present scientists only in specific situations. Serial biospecimens from patients with large associated clinical data concerning voluptuary habits, environmental exposure, anthropomorphic information are needed to meet the even more specific projects the scientists are planning. The hypothesis of activation of specific sections in ranked journals aimed to facilitate the communication between partners interested in finding/collecting ad hoc biospecimens is discussed.
Collapse
Affiliation(s)
- Angelo Virgilio Paradiso
- Oncologia Medica Indirizzo Sperimentale & Direzione Biobanca, Istituto Tumori G Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bari, Italy.
| | - Maria Grazia Daidone
- Department Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto NazionaleTumori, Milan, Italy
| | - Vincenzo Canzonieri
- Pathology Unit and Biobank, Centro Riferimento Oncologico (CRO), IRCCS, National Cancer Institute, Aviano, Italy
| | - Alfredo Zito
- Pathology Unit, Istituto Tumori G Paolo II, IRCCS, Bari, Italy
| |
Collapse
|
19
|
Ling R, Rush A, Carter C, Carpenter J, Watson PH, Byrne JA, Searles A. An Australian Biobank Certification Scheme: A Study of Economic Costs to Participating Biobanks. Biopreserv Biobank 2018; 16:53-58. [DOI: 10.1089/bio.2017.0095] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Rod Ling
- Health Research Economics, Hunter Medical Research Institute, New Lambton, Heights, NSW, Australia
- School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, Australia
| | - Amanda Rush
- Children's Cancer Research Unit, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Candace Carter
- NSW Health Pathology Biobanking Services, NSW Health Pathology, Chatswood, NSW, Australia
| | - Jane Carpenter
- NSW Health Pathology Biobanking Services, NSW Health Pathology, Chatswood, NSW, Australia
| | - Peter H. Watson
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, Canada
| | - Jennifer A. Byrne
- Children's Cancer Research Unit, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia
- Discipline of Child and Adolescent Health, University of Sydney, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Andrew Searles
- Health Research Economics, Hunter Medical Research Institute, New Lambton, Heights, NSW, Australia
- School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, Australia
| |
Collapse
|
20
|
Hartman V, Castillo-Pelayo T, Babinszky S, Dee S, Leblanc J, Matzke L, O'Donoghue S, Carpenter J, Carter C, Rush A, Byrne J, Barnes R, Mes-Messons AM, Watson P. Is Your Biobank Up to Standards? A Review of the National Canadian Tissue Repository Network Required Operational Practice Standards and the Controlled Documents of a Certified Biobank. Biopreserv Biobank 2018; 16:36-41. [DOI: 10.1089/bio.2017.0065] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Affiliation(s)
- Victoria Hartman
- Tumour Tissue Repository, BC Cancer Agency, Victoria, BC, Canada
| | | | - Sindy Babinszky
- Tumour Tissue Repository, BC Cancer Agency, Victoria, BC, Canada
| | - Simon Dee
- Tumour Tissue Repository, BC Cancer Agency, Victoria, BC, Canada
| | - Jodi Leblanc
- Tumour Tissue Repository, BC Cancer Agency, Victoria, BC, Canada
| | - Lise Matzke
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | | | - Jane Carpenter
- NSW Health Pathology Biobanking Services, Chatswood, NSW, Australia
| | - Candace Carter
- University of Sydney NHMRC Clinical Trials Centre, Camperdown, NSW, Australia
| | - Amanda Rush
- Children's Cancer Research Unit, Kids Research Institute, The Children's Hospital at Westmead, NSW, Australia
| | - Jennifer Byrne
- Children's Cancer Research Unit, Kids Research Institute, The Children's Hospital at Westmead, NSW, Australia
- University of Sydney Discipline of Child and Adolescent Health, The Children's Hospital at Westmead, NSW, Australia
| | - Rebecca Barnes
- Canadian Tissue Repository Network, BC Cancer Agency, Victoria, BC, Canada
| | | | - Peter Watson
- Tumour Tissue Repository, BC Cancer Agency, Victoria, BC, Canada
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Canadian Tissue Repository Network, BC Cancer Agency, Victoria, BC, Canada
| |
Collapse
|
21
|
Gormally E, Hardy I, Caboux E, di Donato JH, Hainaut P, Hofman P. Training the Next Generation of Biobankers: A Two-Year Master's Course in the Management of Biobanks. Biopreserv Biobank 2017; 15:438-450. [PMID: 28922617 DOI: 10.1089/bio.2017.0002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The growing complexity of biobanking requires dedicated professional staff who are trained in multiple aspects of the biobanking process, including technical, managerial, regulatory, and ethical aspects, and who have a good understanding of the challenges of biospecimen research, but also of the challenges related to the sustainability of future biobanks. Up to the present, biobanking staff have been trained in an ad-hoc manner, usually through specific short duration courses, for example, summer schools. In this article, we describe the development/establishment of a systematic 2-year training program at the Master level intended for students with a background in life sciences and providing them with a professional qualification as a "Biobank Manager." This course was developed in 2010 as a joint initiative of the Catholic University of Lyon and the University of Nice-Sophia-Antipolis (France). The multidisciplinary training offers courses on biobank design and infrastructure, on pre- and postanalytical processing of different types of biospecimens, on protocol development, on ethical and regulatory aspects, as well as an introduction to epidemiology and translational research. In parallel, students also receive generic training in management, budget planning, data analysis, and statistics, as well as 11 months of hands-on training in various biobanks handling human, animal, plant, or microbial biospecimens. Four groups of students have graduated since 2012, for a total of 44 students, who all found jobs in biobanking within 6 months of graduation.
Collapse
Affiliation(s)
- Emmanuelle Gormally
- 1 Université de Lyon , UMRS 449; Laboratoire de Biologie Générale, Université Catholique de Lyon; Reproduction et Développement Comparé, EPHE, Lyon, France
- 2 Ecole Supérieure de Biologie-Biochimie-Biotechnologies, Université Catholique de Lyon , Lyon, France
| | - Isabelle Hardy
- 1 Université de Lyon , UMRS 449; Laboratoire de Biologie Générale, Université Catholique de Lyon; Reproduction et Développement Comparé, EPHE, Lyon, France
- 2 Ecole Supérieure de Biologie-Biochimie-Biotechnologies, Université Catholique de Lyon , Lyon, France
| | - Elodie Caboux
- 3 International Agency for Research on Cancer , Lyon, France
| | | | - Pierre Hainaut
- 5 Institut for Advanced Biosciences, INSERM 1209, UMR CNRS 5309, Université Grenoble-Alpes , Grenoble, France
| | - Paul Hofman
- 6 University Côte d'Azur, Hospital-Related Biobank (BB-0033-00025), Laboratory of Clinical and Experimental Pathology and FHU OncoAge, Nice University Center Hospital , Nice, France
| |
Collapse
|
22
|
Yang L, Chen Y, Yu C, Shen B. Biobanks and Their Clinical Application and Informatics Challenges. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 939:241-257. [PMID: 27807750 DOI: 10.1007/978-981-10-1503-8_10] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Biobanks are one of the most important biomedical research resources and contribute to the development of biomarker detection, molecular diagnosis, translational medicine, and multidisciplinary disease research, as well as studies of interactions between genetic and environmental or lifestyle factors. Aiming for the wide clinical application of biobanks, biobanking efforts have recently switched from a focus on accumulating samples to both formalizing and sustaining collections in light of the rapid progress in the fields of personalized medicine and bioinformatics analysis. With the emergence of novel molecular diagnostic technologies, although the bioinformatics platform of biobanks ensures reliable bioinformatics analysis of patient samples, there are a series of challenges facing biobanks in terms of the overall harmonization of policies, integrated processes, and local informatics solutions across the network. Further, there is a controversy regarding the increased role of ethical boards, governance, and accreditation bodies in ensuring that collected samples have sufficient informatics capabilities to be used in biobanks. In this volume, we present a selection of current issues on the inevitable challenges of the clinical application of biobanks in informatics.
Collapse
Affiliation(s)
- Lan Yang
- Center for Systems Biology, Soochow University, No. 1 Shizi Street, 206, 215006, Suzhou, Jiangsu, China
| | - Yalan Chen
- Center for Systems Biology, Soochow University, No. 1 Shizi Street, 206, 215006, Suzhou, Jiangsu, China.,Department of Medical Informatics, School of Medicine, Nantong University, Nantong, Jiangsu, China
| | - Chunjiang Yu
- Suzhou Industrial Park Institute of Services Outsourcing, No. 99 Ruoshui Road, Suzhou Industrial Park, Suzhou, 215123, Jiangsu, China
| | - Bairong Shen
- Center for Systems Biology, Soochow University, No. 1 Shizi Street, 206, 215006, Suzhou, Jiangsu, China.
| |
Collapse
|
23
|
Barnes RO, Shea KE, Watson PH. The Canadian Tissue Repository Network Biobank Certification and the College of American Pathologists Biorepository Accreditation Programs: Two Strategies for Knowledge Dissemination in Biobanking. Biopreserv Biobank 2017; 15:9-16. [DOI: 10.1089/bio.2016.0021] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Affiliation(s)
- Rebecca O. Barnes
- Canadian Tissue Repository Network, Vancouver, British Columbia, Canada
| | - Katheryn E. Shea
- Global Operations, BioStorage Technologies, Indianapolis, Indiana
| | - Peter H. Watson
- Canadian Tissue Repository Network, Vancouver, British Columbia, Canada
- Tumour Tissue Repository BC Cancer Agency, Victoria, British Columbia, Canada
- Office of Biobank Education and Research, Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
24
|
Simeon-Dubach D, Goldring K, Henderson MK. Trends in Biobanking Business Planning: Initial Results of a Survey of Biobankers. Biopreserv Biobank 2016; 15:72-74. [PMID: 27936871 DOI: 10.1089/bio.2016.0080] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Gee S, Oliver R, Corfield J, Georghiou L, Yuille M. Biobank Finances: A Socio-Economic Analysis and Review. Biopreserv Biobank 2016; 13:435-51. [PMID: 26697914 DOI: 10.1089/bio.2015.0030] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
This socio-economic study is based on the widely held view that there is an inadequate supply of human biological samples that is hampering biomedical research development and innovation (RDI). The potential value of samples and the associated data are thus not being realized. We aimed to examine whether the financing of biobanks contributes to this problem and then to propose a national solution. We combined three methods: a qualitative case study; literature analysis; and informal consultations with experts. The case study enabled an examination of the complex institutional arrangements for biobanks, with a particular focus on cost models. For the purposes of comparison, a typology for biobanks was developed using the three methods. We found that it is not possible to apply a standard cost model across the diversity of biobanks, and there is a deficit in coordination and sustainability and an excess of complexity. We propose that coordination across this diversity requires dedicated resources for a national biobanking distributed research infrastructure. A coordination center would establish and improve standards and support a national portal for access. This should be financed centrally by public funds, possibly supplemented by industrial funding. We propose that: a) sample acquisition continues to be costed into projects and project proposals to ensure biobanking is driven by research needs; b) core biobanking activities and facilities be supported by central public funds distributed directly to host public institutions; and c) marginal costs for access be paid for by the user.
Collapse
Affiliation(s)
- Sally Gee
- 1 Manchester Institute of Innovation Research, Manchester Business School, The University of Manchester , Manchester, United Kingdom
| | - Rob Oliver
- 2 Research and Development Directorate, Salford Royal Hospitals NHS Trust , Salford, United Kingdom
| | | | - Luke Georghiou
- 1 Manchester Institute of Innovation Research, Manchester Business School, The University of Manchester , Manchester, United Kingdom
| | - Martin Yuille
- 4 Center for Integrated Genomic Medical Research, Institute of Population Health, The University of Manchester , Manchester, United Kingdom
| |
Collapse
|
26
|
Simeon-Dubach D, Zeisberger SM, Hoerstrup SP. Quality Assurance in Biobanking for Pre-Clinical Research. Transfus Med Hemother 2016; 43:353-357. [PMID: 27781023 DOI: 10.1159/000448254] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 07/04/2016] [Indexed: 12/29/2022] Open
Abstract
It is estimated that not less than USD 28 billion are spent each year in the USA alone on irreproducible pre-clinical research, which is not only a fundamental loss of investment and resources but also a strong inhibitor of efficiency for upstream processes regarding the translation towards clinical applications and therapies. The issues and cost of irreproducibility has mainly been published on pre-clinical research. In contrast to pre-clinical research, test material is often being transferred into humans in clinical research. To protect treated human subjects and guarantee a defined quality standard in the field of clinical research, the manufacturing and processing infrastructures have to strictly follow and adhere to certain (inter-)national quality standards. It is assumed and suggested by the authors that by an implementation of certain quality standards within the area of pre-clinical research, billions of USD might be saved and the translation phase of promising pre-clinical results towards clinical applications may substantially be improved. In this review, we discuss how an implementation of a quality assurance (QA) management system might positively improve sample quality and sustainability within pre-clinically focused biobank infrastructures. Biobanks are frequently positioned at the very beginning of the biomedical research value chain, and, since almost every research material has been stored in a biobank during the investigated life cycle, biobanking seems to be of substantial importance from this perspective. The role model of a QA-regulated biobank structure can be found in biobanks within the context of clinical research organizations such as in regenerative medicine clusters.
Collapse
Affiliation(s)
| | - Steffen M Zeisberger
- Wyss Translational Center Zurich, Regenerative Medicine Technologies Platform, University of Zurich and ETH Zurich, Zurich, Switzerland
| | - Simon P Hoerstrup
- Wyss Translational Center Zurich, University of Zurich and ETH Zurich, and Institute of Regenerative Medicine, University of Zurich, Zurich, Switzerland
| |
Collapse
|
27
|
Matzke LAM, Babinszky S, Slotty A, Meredith A, Castillo-Pelayo T, Henderson MK, Simeon-Dubach D, Schacter B, Watson PH. Biospecimen User Fees: Global Feedback on a Calculator Tool. Biopreserv Biobank 2016; 15:57-64. [PMID: 27576065 DOI: 10.1089/bio.2016.0027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The notion of attributing user fees to researchers for biospecimens provided by biobanks has been discussed frequently in the literature. However, the considerations around how to attribute the cost for these biospecimens and data have, until recently, not been well described. Common across most biobank disciplines are similar factors that influence user fees such as capital and operating costs, internal and external demand, and market competition. A biospecimen user fee calculator tool developed by CTRNet, a tumor biobank network, was published in 2014 and is accessible online at www.biobanking.org . The next year a survey was launched that tested the applicability of this user fee tool among a global health research biobank user base, including both cancer and noncancer biobanking. Participants were first asked to estimate user fee pricing for three hypothetical user scenarios based on their biobanking experience (estimated pricing) and then to calculate fees for the same scenarios using the calculator tool (calculated pricing). Results demonstrated variation in estimated pricing that was reduced by calculated pricing. These results are similar to those found in a similar previous study restricted to a group of Canadian tumor biobanks. We conclude that the use of a biospecimen user fee calculator contributes to reduced variation of user fees and for biobank groups (e.g., biobank networks), could become an important part of a harmonization strategy.
Collapse
Affiliation(s)
- Lise A M Matzke
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, Canada
| | - Sindy Babinszky
- 2 Tumour Tissue Repository (TTR), BC Cancer Agency , Vancouver Island Centre, Victoria, Canada
| | - Alex Slotty
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, Canada
| | - Anna Meredith
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, Canada
| | - Tania Castillo-Pelayo
- 2 Tumour Tissue Repository (TTR), BC Cancer Agency , Vancouver Island Centre, Victoria, Canada
| | | | | | - Brent Schacter
- 5 Canadian Tissue Repository Network, CancerCare Manitoba, Winnipeg, Canada
| | - Peter H Watson
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, Canada .,2 Tumour Tissue Repository (TTR), BC Cancer Agency , Vancouver Island Centre, Victoria, Canada .,5 Canadian Tissue Repository Network, CancerCare Manitoba, Winnipeg, Canada
| |
Collapse
|
28
|
Rush A, Byrne JA. Quality and reporting practices in an Australian cancer biobank cohort. Clin Biochem 2016; 49:492-497. [DOI: 10.1016/j.clinbiochem.2015.12.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2015] [Revised: 12/11/2015] [Accepted: 12/15/2015] [Indexed: 12/16/2022]
|
29
|
Matzke LAM, Fombonne B, Watson PH, Moore HM. Fundamental Considerations for Biobank Legacy Planning. Biopreserv Biobank 2016; 14:99-106. [PMID: 26890981 DOI: 10.1089/bio.2015.0073] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Biobanking in its various forms is an activity involving the collection of biospecimens and associated data and their storage for differing lengths of time before use. In some cases, biospecimens are immediately used, but in others, they are stored typically for the term of a specified project or in perpetuity until the materials are used up or declared to be of little scientific value. Legacy planning involves preparing for the phase that follows either biobank closure or a significant change at an operational level. In the case of a classical finite collection, this may be brought about by the completion of the initial scientific goals of a project, a loss of funding, or loss of or change in leadership. Ultimately, this may require making a decision about when and where to transfer materials or whether to destroy them. Because biobanking in its entirety is a complex endeavour, legacy planning touches on biobank operations as well as ethical, legal, financial, and governance parameters. Given the expense and time that goes into setting up and maintaining biobanks, coupled with the ethical imperative to appropriately utilize precious resources donated to research, legacy planning is an activity that every biobanking entity should think about. This article describes some of the fundamental considerations for preparing and executing a legacy plan, and we envisage that this article will facilitate dialogue to help inform best practices and policy development in the future.
Collapse
Affiliation(s)
- Lise Anne Marie Matzke
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, British Columbia, Canada
| | - Benjamin Fombonne
- 2 Biorepositories and Biospecimen Research Branch, National Cancer Institute , Bethesda, Maryland
| | - Peter Hamilton Watson
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, British Columbia, Canada .,3 Tumour Tissue Repository (TTR), BC Cancer Agency, Vancouver Island Centre, Victoria , British Columbia, Canada
| | - Helen Marie Moore
- 2 Biorepositories and Biospecimen Research Branch, National Cancer Institute , Bethesda, Maryland
| |
Collapse
|
30
|
Nussbeck SY, Rabone M, Benson EE, Droege G, Mackenzie-Dodds J, Lawlor RT. "Life in Data"--Outcome of a Multi-Disciplinary, Interactive Biobanking Conference Session on Sample Data. Biopreserv Biobank 2016; 14:56-64. [PMID: 26808538 PMCID: PMC4761830 DOI: 10.1089/bio.2015.0061] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
INTRODUCTION Clinical, biodiversity, and environmental biobanks share many data standards, but there is a lack of harmonization on how data are defined and used among biobank fields. This article reports the outcome of an interactive, multidisciplinary session at a meeting of the European, Middle Eastern, and African Society for Biopreservation and Biobanking (ESBB) designed to encourage a 'learning-from-each-other' approach to achieve consensus on data needs and data management across biobank communities. MATERIALS, METHODS, AND RESULTS The Enviro-Bio and ESBBperanto Working Groups of the ESBB co-organized an interactive session at the 2013 conference (Verona, Italy), presenting data associated with biobanking processes, using examples from across different fields. One-hundred-sixty (160) diverse biobank participants were provided electronic voting devices with real-time screen display of responses to questions posed during the session. The importance of data standards and robust data management was recognized across the conference cohort, along with the need to raise awareness about these issues within and across different biobank sectors. DISCUSSION AND CONCLUSION While interactive sessions require a commitment of time and resources, and must be carefully coordinated for consistency and continuity, they stimulate the audience to be pro-active and direct the course of the session. This effective method was used to gauge opinions about significant topics across different biobanking communities. The votes revealed the need to: (a) educate biobanks in the use of data management tools and standards, and (b) encourage a more cohesive approach for how data and samples are tracked, exchanged, and standardized across biobanking communities. Recommendations for future interactive sessions are presented based on lessons learned.
Collapse
Affiliation(s)
- Sara Y. Nussbeck
- Department of Medical Informatics and UMG Biobank, University Medical Center Göttingen, Göttingen, Germany
| | - Muriel Rabone
- Department of Life Sciences, Natural History Museum, London, United Kingdom
| | - Erica E. Benson
- Damar Research Scientists, Cuparmuir, Fife, Scotland, United Kingdom
| | - Gabriele Droege
- Botanic Garden and Botanical Museum Berlin-Dahlem, Freie Universität Berlin, Berlin, Germany
| | | | - Rita T. Lawlor
- ARC-Net Applied Research on Cancer Centre, University of Verona, Verona, Italy
| |
Collapse
|
31
|
A critical analysis of cancer biobank practices in relation to biospecimen quality. Biophys Rev 2015; 7:369-378. [PMID: 28510101 DOI: 10.1007/s12551-015-0178-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Accepted: 09/17/2015] [Indexed: 12/26/2022] Open
Abstract
There are concerns that a substantial proportion of published research data is not reproducible, which may partially explain the frequent failure to translate pre-clinical results to clinical care. High-quality cancer biospecimens are needed for robust, reproducible research findings, with most researchers obtaining these specimens from cancer biobanks or tumour banks. This review provides an overview of the types of quality control (QC) activities conducted within cancer biobanks that pertain to biospecimen quality and of biospecimen quality reporting tools, including SPREC and BRISQ. We examine how QC assay results and other biospecimen data are communicated from biobanks to researchers, and whether these activities lead to improved biospecimen quality reporting within the literature and/or to improved research outcomes. We also discuss operational factors that limit QC activities within biobanks and evidence gaps requiring further research. In summary, whereas the provision of quality biospecimens is a common aim of cancer biobanks, QC activities remain underreported and are rarely discussed in the literature, compared with other aspects of biobank operations. Further research is required to determine how biobanks can most efficiently optimise biospecimen quality, and how communication between biobanks and researchers can be improved.
Collapse
|
32
|
Meredith AJ, Slotty A, Matzke L, Babinszky S, Watson PH. A Model to Estimate Frozen Tissue Collection Targets in Biobanks to Support Cancer Research. Biopreserv Biobank 2015; 13:356-62. [DOI: 10.1089/bio.2014.0081] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Affiliation(s)
- Anna J. Meredith
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, BC Cancer Agency and UBC, Vancouver, British Columbia, Canada
| | - Alex Slotty
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, BC Cancer Agency and UBC, Vancouver, British Columbia, Canada
| | - Lise Matzke
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, BC Cancer Agency and UBC, Vancouver, British Columbia, Canada
| | - Sindy Babinszky
- Tumour Tissue Repository, Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada
| | - Peter H. Watson
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, BC Cancer Agency and UBC, Vancouver, British Columbia, Canada
- Tumour Tissue Repository, Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada
| |
Collapse
|
33
|
Warth R, Perren A. Construction of a business model to assure financial sustainability of biobanks. Biopreserv Biobank 2015; 12:389-94. [PMID: 25496150 DOI: 10.1089/bio.2014.0057] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Biobank-suisse (BBS) is a collaborative network of biobanks in Switzerland. Since 2005, the network has worked with biobank managers towards a Swiss biobanking platform that harmonizes structures and procedures. The work with biobank managers has shown that long-term, sustainable financing is difficult to obtain. In this report, three typical biobank business models are identified and their characteristics analyzed. Five forces analysis was used to understand the competitive environment of biobanks. Data provided by OECD was used for financial estimations. The model was constructed using the business model canvas tool. The business models identified feature financing influenced by the economic situation and the research budgets in a given country. Overall, the competitive environment for biobanks is positive. The bargaining power with the buyer is negative since price setting and demand prediction is difficult. In Switzerland, the healthcare industry collects approximately 5600 U.S. dollars per person and year. If each Swiss citizen paid 0.1% (or 5 U.S. dollars) of this amount to Swiss biobanks, 45 million U.S. dollars could be collected. This compares to the approximately 10 million U.S. dollars made available for cohort studies, longitudinal studies, and pathology biobanks through science funding. With the same approach, Germany, the United States, Canada, France, and the United Kingdom could collect 361, 2634, 154, 264, and 221 million U.S. dollars, respectively. In Switzerland and in other countries, an annual fee less than 5 U.S. dollars per person is sufficient to provide biobanks with sustainable financing. This inspired us to construct a business model that not only includes the academic and industrial research sectors as customer segment, but also includes the population. The revenues would be collected as fees by the healthcare system. In Italy and Germany, a small share of healthcare spending is already used to finance selected clinical trials. The legal frameworks could serve as templates for the business model proposed here.
Collapse
|
34
|
Abstract
In March 2014 the European Society of Radiology (ESR) established a dedicated working group (ESR WG on Imaging Biobanks) aimed at monitoring the existing imaging biobanks in Europe, promoting the federation of imaging biobanks and communication of their findings in a white paper. The WG provided the following statements: (1) Imaging biobanks can be defined as "organised databases of medical images and associated imaging biomarkers (radiology and beyond) shared among multiple researchers, and linked to other biorepositories". (2) The immediate purpose of imaging biobanks should be to allow the generation of imaging biomarkers for use in research studies and to support biological validation of existing and novel imaging biomarkers. (3) A long-term scope of imaging biobanks should be the creation of a network/federation of such repositories integrated with the already-existing biobanking network. The aim of the WG was to investigate the existence, consistency, geographical distribution and type of imaging biobanks in Europe. A survey among ESR members resulted in the identification of 27 imaging biobanks, mostly disease-oriented and designed for research and clinical reference. In 80 % access to imaging biobanks is restricted. Key points • Imaging biobanks are "shared databases of imaging biomarkers, linked to biorepositories".• Exploitation of traditional and imaging biobanks is meaningful for "personalised medicine".• A European imaging biobank network would significantly boost research in the imaging domain.
Collapse
|
35
|
Rush A, Christiansen JH, Farrell JP, Goode SM, Scott RJ, Spring KJ, Byrne JA. Biobank Classification in an Australian Setting. Biopreserv Biobank 2015; 13:212-8. [DOI: 10.1089/bio.2015.0007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Affiliation(s)
- Amanda Rush
- Children's Cancer Research Unit, Kids Research Institute, NSW, Australia
| | | | | | - Susan M. Goode
- Hunter Medical Research Institute, New Lambton, NSW, Australia
| | - Rodney J. Scott
- Hunter Medical Research Institute, New Lambton, NSW, Australia
| | - Kevin J. Spring
- Ingham Institute, Liverpool, NSW, Australia
- University of Western Sydney, Liverpool Clinical School, Liverpool, NSW, Australia
| | - Jennifer A. Byrne
- Children's Cancer Research Unit, Kids Research Institute, NSW, Australia
- University of Sydney Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Westmead, NSW, Australia
| |
Collapse
|
36
|
Castillo-Pelayo T, Babinszky S, LeBlanc J, Watson PH. The Importance of Biobanking in Cancer Research. Biopreserv Biobank 2015; 13:172-7. [DOI: 10.1089/bio.2014.0061] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Affiliation(s)
- Tania Castillo-Pelayo
- Tumour Tissue Repository, Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada
| | - Sindy Babinszky
- Tumour Tissue Repository, Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada
| | - Jodi LeBlanc
- Tumour Tissue Repository, Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada
| | - Peter H Watson
- Tumour Tissue Repository, Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, BC Cancer Agency and UBC, Vancouver, British Columbia, Canada
| |
Collapse
|
37
|
Matzke L, Dee S, Bartlett J, Damaraju S, Graham K, Johnston R, Mes-Masson AM, Murphy L, Shepherd L, Schacter B, Watson PH. A practical tool for modeling biospecimen user fees. Biopreserv Biobank 2015; 12:234-9. [PMID: 25162459 DOI: 10.1089/bio.2014.0008] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The question of how best to attribute the unit costs of the annotated biospecimen product that is provided to a research user is a common issue for many biobanks. Some of the factors influencing user fees are capital and operating costs, internal and external demand and market competition, and moral standards that dictate that fees must have an ethical basis. It is therefore important to establish a transparent and accurate costing tool that can be utilized by biobanks and aid them in establishing biospecimen user fees. To address this issue, we built a biospecimen user fee calculator tool, accessible online at www.biobanking.org . The tool was built to allow input of: i) annual operating and capital costs; ii) costs categorized by the major core biobanking operations; iii) specimen products requested by a biobank user; and iv) services provided by the biobank beyond core operations (e.g., histology, tissue micro-array); as well as v) several user defined variables to allow the calculator to be adapted to different biobank operational designs. To establish default values for variables within the calculator, we first surveyed the members of the Canadian Tumour Repository Network (CTRNet) management committee. We then enrolled four different participants from CTRNet biobanks to test the hypothesis that the calculator tool could change approaches to user fees. Participants were first asked to estimate user fee pricing for three hypothetical user scenarios based on their biobanking experience (estimated pricing) and then to calculate fees for the same scenarios using the calculator tool (calculated pricing). Results demonstrated significant variation in estimated pricing that was reduced by calculated pricing, and that higher user fees are consistently derived when using the calculator. We conclude that adoption of this online calculator for user fee determination is an important first step towards harmonization and realistic user fees.
Collapse
Affiliation(s)
- Lise Matzke
- 1 University of British Columbia Office of Biobank Education and Research , Vancouver, British Columbia, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Nussbeck SY, Skrowny D, O'Donoghue S, Schulze TG, Helbing K. How to design biospecimen identifiers and integrate relevant functionalities into your biospecimen management system. Biopreserv Biobank 2015; 12:199-205. [PMID: 24955734 DOI: 10.1089/bio.2013.0085] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Effective tracking of biospecimens within a biobank requires that each biospecimen has a unique identifier (ID). This ID can be found on the sample container as well as in the biospecimen management system. In the latter, the biospecimen ID is the key to annotation data such as location, quality, and sample processing. Guidelines such as the Best Practices from the International Society of Biological and Environmental Repositories only state that a unique identifier should be issued for each sample. However, to our knowledge, all guidelines lack a specific description of how to actually generate such an ID and how this can be supported by an IT system. Here, we provide a guide for biobankers on how to generate a biospecimen ID for your biobank. We also provide an example of how to apply this guide using a longitudinal multi-center research project (and its biobank). Starting with a description of the biobank's purpose and workflows through to collecting requirements from stakeholders and relevant documents (i.e., guidelines or data protection concepts), and existing IT-systems, we describe in detail how a concept to develop an ID system can be developed from this information. The concept contains two parts: one is the generation of the biospecimen ID according to the requirements of stakeholders, existing documentation such as guidelines or data protection concepts, and existing IT-infrastructures, and the second is the implementation of the biospecimen IDs and related functionalities covering the handling of individual biospecimens within an existing biospecimen management system. From describing the concept, the article moves on to how the new concept supports both existing or planned biobank workflows. Finally, the implementation and validation step is outlined to the reader and practical hints are provided for each step.
Collapse
Affiliation(s)
- Sara Y Nussbeck
- 1 Department of Medical Informatics, University Medical Center Göttingen , Göttingen, Germany
| | | | | | | | | |
Collapse
|
39
|
Watson PH. Biobank classification: communicating biorepository diversity. Biopreserv Biobank 2015; 12:163-4. [PMID: 24955732 DOI: 10.1089/bio.2014.1231] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Boyer GJ, Whipple W, Cadigan RJ, Henderson GE. Biobanks in the United States: how to identify an undefined and rapidly evolving population. Biopreserv Biobank 2015; 10:511-7. [PMID: 24845137 DOI: 10.1089/bio.2012.0034] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
As part of a larger organizational study, we sought to survey biobanks in the United States. However, we encountered two problems with this population. First, no common definition of biobanks exists. Second, no census is available of these facilities from which to sample in order to implement a survey. In light of these problems, we employed a multifaceted approach using electronic searches of PubMed, RePORTER, and Google. In addition, we systematically searched for biobanks housed within universities that have NIH-designated Clinical and Translational Science Awards (CTSA). We expanded this part of the search by looking for biobanks among all members of the American Association of Medical Colleges (AAMC). Finally, we added banks to our database found previously by other researchers and banks found via correspondence with our colleagues. Our search strategy produced a database of 624 biobanks for which we were able to confirm contact information in order to conduct our online survey. Another 140 biobanks were identified but did not respond to our requests to confirm their existence or contact information. In order to maximize both the uniqueness of banks found and the greatest return on effort for each search, we suggest targeting resources that are already organized. In our work, these included the CTSA, AAMC, and part of the Google searches. We contend that our search provides a model for analysis of new fields of research and/or rapidly evolving industries. Furthermore, our approach demonstrates that with the appropriate tools it is possible to develop a systematic and comprehensive database to investigate undefined populations.
Collapse
Affiliation(s)
- Gregory J Boyer
- 1 Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina
| | | | | | | |
Collapse
|
41
|
Matzke EAM, O'Donoghue S, Barnes RO, Daudt H, Cheah S, Suggitt A, Bartlett J, Damaraju S, Johnston R, Murphy L, Shepherd L, Mes-Masson AM, Schacter B, Watson PH. Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank 2015; 10:426-32. [PMID: 24845043 DOI: 10.1089/bio.2012.0026] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Two core aspects of the discipline of biobanking are biospecimen quality and good governance. Meeting the demands of both sample quality and governance can be challenging, especially in a resource limited environment. Frequently, differences between biobank processes reduce the ability for cooperative action and specimen sharing with researchers. In the Canadian context, we have made an attempt to identify these gaps and have provided a framework to support excellence, initially for tumor biobanks. The Canadian Tumour Repository Network (CTRNet) was established with funding from the Canadian Institute of Health Sciences (CIHR) Institute of Cancer Research (ICR) to foster translational research through improved access to high quality tumour biospecimens. Consistent with this mandate, CTRNet has focused on the establishment and deployment of common standards to harmonize biospecimen quality and approaches to governance. More recently, CTRNet has implemented a certification program to communicate these standards in conjunction with simultaneous exposure to education focusing on the rationale and foundations underlying these standards. The CTRNet certification program comprises registration and certification steps as two linked phases. In the registration phase, launched in November 2011, biobanks are registered into the system and individuals complete an introductory educational module. In the subsequent certification phase, the type of biobank is classified and assigned relevant educational modules and adoption of relevant standards of practice is confirmed through review of documentation including policies and protocols that address the CTRNet Required Operational Practices (ROPs). An important feature of the program is that it is intended for all types of tumor biobanks, so the scope and extent of assessment is scaled to the type of biobank. This program will provide an easily adoptable and flexible mechanism to communicate common standards through education and address both quality assurance and governance across the broad spectrum of biobanks.
Collapse
Affiliation(s)
- Elizabeth A M Matzke
- 1 University of British Columbia Office of Biobank Education and Research , Vancouver, British Columbia, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Somiari SB, Somiari RI. The Future of Biobanking: A Conceptual Look at How Biobanks Can Respond to the Growing Human Biospecimen Needs of Researchers. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2015; 864:11-27. [PMID: 26420610 DOI: 10.1007/978-3-319-20579-3_2] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Biobanking of human biological specimens has evolved from the simple private collection of often poorly annotated residual clinical specimens, to well annotated and organized collections setup by commercial and not-for-profit organizations. The activities of biobanks is now the focus of international and government agencies in recognition of the need to adopt best practices and provide scientific, ethical and legal guidelines for the industry. The demand for more, high quality and clinically annotated biospecimens will increase, primarily due to the unprecedented level of genomic, post genomic and personalized medicine research activities going on. Demand for more biospecimens provides new challenges and opportunities for developing strategies to build biobanking into a business that is better able to supply the biospecimen needs of the future. A paradigm shift is required particularly in organization and funding, as well as in how and where biospecimens are collected, stored and distributed. New collection sites, organized as Research Ready Hospitals (RRHs) and new public-private partnership models are needed for sustainability and increased biospecimen availability. Biobanks will need to adopt industry-wide standard operating procedures, better and "non-destructive" methods for quality assessment, less expensive methods for sample storage/distribution, and objective methods to manage scarce biospecimens. Ultimately, the success of future biobanks will rely greatly on the success of public-private partnerships, number and diversity of available biospecimens, cost management and the realization that an effective biobank is one that provides high quality and affordable biospecimens to drive research that leads to better health and quality of life for all.
Collapse
|
43
|
Challenges in Developing a Cancer Oriented-Biobank: Experience from a 17 Year-Old Cancer Biobank in Sao Paulo, Brazil. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2015; 864:115-23. [DOI: 10.1007/978-3-319-20579-3_9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
44
|
Watson PH, Nussbeck SY, Carter C, O'Donoghue S, Cheah S, Matzke LAM, Barnes RO, Bartlett J, Carpenter J, Grizzle WE, Johnston RN, Mes-Masson AM, Murphy L, Sexton K, Shepherd L, Simeon-Dubach D, Zeps N, Schacter B. A framework for biobank sustainability. Biopreserv Biobank 2014; 12:60-8. [PMID: 24620771 DOI: 10.1089/bio.2013.0064] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Each year funding agencies and academic institutions spend millions of dollars and euros on biobanking. All funding providers assume that after initial investments biobanks should be able to operate sustainably. However the topic of sustainability is challenging for the discipline of biobanking for several major reasons: the diversity in the biobanking landscape, the different purposes of biobanks, the fact that biobanks are dissimilar to other research infrastructures and the absence of universally understood or applicable value metrics for funders and other stakeholders. In this article our aim is to delineate a framework to allow more effective discussion and action around approaches for improving biobank sustainability. The term sustainability is often used to mean fiscally self-sustaining, but this restricted definition is not sufficient for biobanking. Instead we propose that biobank sustainability should be considered within a framework of three dimensions - financial, operational, and social. In each dimension, areas of focus or elements are identified that may allow different types of biobanks to distinguish and evaluate the relevance, likelihood, and impact of each element, as well as the risks to the biobank of failure to address them. Examples of practical solutions, tools and strategies to address biobank sustainability are also discussed.
Collapse
Affiliation(s)
- Peter H Watson
- 1 University of British Columbia Office of Biobank Education and Research , Vancouver, British Columbia, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Barnes RO, Schacter B, Kodeeswaran S, Watson PH. Funding sources for Canadian biorepositories: the role of user fees and strategies to help fill the gap. Biopreserv Biobank 2014; 12:300-5. [PMID: 25314324 DOI: 10.1089/bio.2014.0052] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Biorepositories, the coordinating hubs for the collection and annotation of biospecimens, are under increasing financial pressure and are challenged to remain sustainable. To gain a better understanding of the current funding situation for Canadian biorepositories and the relative contributions they receive from different funding sources, the Canadian Tumour Repository Network (CTRNet) conducted two surveys. The first survey targeted CTRNet's six main nodes to ascertain the relative funding sources and levels of user fees. The second survey was targeted to a broader range of biorepositories (n=45) to ascertain business practices in application of user fees. The results show that >70% of Canadian biorepositories apply user fees and that the majority apply differential fees to different user groups (academic vs. industry, local vs. international). However, user fees typically comprise only 6% of overall operational budgets. We conclude that while strategies to drive up user fee levels need to be implemented, it is essential for the many stakeholders in the biomedical health research sector to consider this issue in order to ensure the ongoing availability of research biospecimens and data that are standardized, high-quality, and that are therefore capable of meeting research needs.
Collapse
Affiliation(s)
- Rebecca O Barnes
- 1 Canadian Tumour Repository Network , Victoria, Winnipeg, Manitoba, Canada
| | | | | | | | | |
Collapse
|
46
|
Biobanking 3.0: evidence based and customer focused biobanking. Clin Biochem 2014; 47:300-8. [PMID: 24406300 DOI: 10.1016/j.clinbiochem.2013.12.018] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Revised: 12/08/2013] [Accepted: 12/13/2013] [Indexed: 01/19/2023]
Abstract
Biobanking is a new and very dynamic field. To achieve long term financial sustainability of biobank infrastructures we propose that a new focus is needed on activities, products and services provided by the biobank that relate to the external stakeholder: biobanking 3.0. Earlier stages of biobanking are biobanking 1.0 (primary focus on the number of biospecimens and data) and biobanking 2.0 (primary focus on the quality of biospecimens and data). Both stages 1.0 and 2.0 are predominantly product oriented areas and have required a mostly internal focus on operational development within the biobank itself. In this paper we will introduce our concept of biobanking 3.0 which capitalizes on the earlier stages but dictates a shift in focus to enhancing the value and impact for the three major sets of external stakeholders (people/patients, funders, and research customers) and creating a path to balanced and planned investment in biobank infrastructure and the sustainability of biobanking. Biobanking 3.0 will improve real understanding as well as perceptions of value across different stakeholders. Patients and donors will appreciate seeing how their biospecimens and data are effectively used for research. Funders will value the ability to plan efficient targeting of funding and to monitor the impact of their support. Researchers will capitalize on the ability to translate their ideas into effective knowledge. Ultimately adoption of biobanking 3.0 will impact on the sustainability in the three main dimensions relevant to biobanking: social sustainability (acceptability), operational sustainability (efficiency), and financial sustainability (accomplishment).
Collapse
|
47
|
Barnes R, Albert M, Damaraju S, de Sousa-Hitzler J, Kodeeswaran S, Mes-Masson AM, Watson P, Schacter B. Generating a comprehensive set of standard operating procedures for a biorepository network-The CTRNet experience. Biopreserv Biobank 2013; 11:387-96. [PMID: 24835369 DOI: 10.1089/bio.2013.0061] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Despite the integral role of biorepositories in fueling translational research and the advancement of medicine, there are significant gaps in harmonization of biobanking practices, resulting in variable biospecimen collection, storage, and processing. This significantly impacts accurate downstream analysis and, in particular, creates a problem for biorepository networks or consortia. The Canadian Tumour Repository Network (CTRNet; www.ctrnet.ca ) is a consortium of Canadian tumor biorepositories that aims to enhance biobanking capacity and quality through standardization. To minimize the issue of variable biobanking practices throughout its network, CTRNet has developed and maintained a comprehensive set of 45 standard operating procedures (SOPs). There were four key elements to the CTRNet SOP development process: 1) an SOP development team was formed from members across CTRNet to co-produce each SOP; 2) a principal author was appointed with responsibility for overall coordination of the SOP development process; 3) the CTRNet Management Committee (composed of principal investigators for each member biorepository) reviewed/revised each SOP completed by the development team; and 4) external expert reviewers provided feedback and recommendations on each SOP. Once final Management Committee approval was obtained, the ratified SOP was published on the CTRNet website for public access. Since the SOPs were first published on the CTRNet website (June 2008), there have been approximately 15,000 downloads of one or more CTRNet SOPs/Policies by users from over 60 countries. In accordance with biobanking best practices, CTRNet performs an exhaustive review of its SOPs at set intervals, to coincide with each granting cycle. The last revision was completed in May 2012.
Collapse
|
48
|
Abstract
The review explores the field of biobanking as it has evolved from a simple collection of frozen specimens to the virtual biobank. Biorepository and biospecimen science has evolved in response to the changing landscape of external regulatory pressures, the advances made in the biological sciences, and the advent of the computer chip. Biospecimen banking is a growing enterprise crucial to health science research and other biological sciences. In this review we discuss the history of biobanking, highlight current and emerging issues, discuss demands and responses, and describe an example of a biobank, the University of California, San Francisco AIDS Specimen Bank that has functioned for 30 years.
Collapse
|
49
|
Henderson GE, Cadigan RJ, Edwards TP, Conlon I, Nelson AG, Evans JP, Davis AM, Zimmer C, Weiner BJ. Characterizing biobank organizations in the U.S.: results from a national survey. Genome Med 2013; 5:3. [PMID: 23351549 PMCID: PMC3706795 DOI: 10.1186/gm407] [Citation(s) in RCA: 141] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2012] [Revised: 12/17/2012] [Accepted: 01/25/2013] [Indexed: 12/22/2022] Open
Abstract
Background Effective translational biomedical research hinges on the operation of 'biobanks,' repositories that assemble, store, and manage collections of human specimens and related data. Some are established intentionally to address particular research needs; many, however, have arisen opportunistically, in a variety of settings and with a variety of expectations regarding their functions and longevity. Despite their rising prominence, little is known about how biobanks are organized and function beyond simple classification systems (government, academia, industry). Methods In 2012, we conducted the first national survey of biobanks in the U.S., collecting information on their origins, specimen collections, organizational structures, and market contexts and sustainability. From a list of 636 biobanks assembled through a multi-faceted search strategy, representatives from 456 U.S. biobanks were successfully recruited for a 30-minute online survey (72% response rate). Both closed and open-ended responses were analyzed using descriptive statistics. Results While nearly two-thirds of biobanks were established within the last decade, 17% have been in existence for over 20 years. Fifty-three percent listed research on a particular disease as the most important reason for establishment; 29% listed research generally. Other reasons included response to a grant or gift, and intent to centralize, integrate, or harmonize existing research structures. Biobank collections are extraordinarily diverse in number and types of specimens and in sources (often multiple) from which they are obtained, including from individuals, clinics or hospitals, public health programs, and research studies. Forty-four percent of biobanks store pediatric specimens, and 36% include postmortem specimens. Most biobanks are affiliated in one or multiple ways with other entities: 88% are part of at least one or more larger organizations (67% of these are academic, 23% hospitals, 13% research institutes). The majority of biobanks seem to fill a particular 'niche' within a larger organization or research area; a minority are concerned about competition for services, although many are worried about underutilization of specimens and long-term funding. Conclusions Effective utilization of biobank collections and effective policies to govern their use will require understanding of the immense diversity found in organizational features, including the very different history and primary goals that many biobanks have.
Collapse
Affiliation(s)
- Gail E Henderson
- Department of Social Medicine, CB 7240, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7240, USA
| | - R Jean Cadigan
- Department of Social Medicine, CB 7240, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7240, USA
| | - Teresa P Edwards
- HW Odum Institute for Research in Social Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3355, USA
| | - Ian Conlon
- Department of Sociology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3355, USA
| | - Anders G Nelson
- Department of Social Medicine, CB 7240, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7240, USA
| | - James P Evans
- Department of Genetics, CB 7264, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7264, USA
| | - Arlene M Davis
- Department of Social Medicine, CB 7240, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7240, USA
| | - Catherine Zimmer
- HW Odum Institute for Research in Social Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3355, USA ; Department of Sociology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3355, USA
| | - Bryan J Weiner
- Department of Health Policy and Management, CB 7411, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7411, USA
| |
Collapse
|
50
|
Kozlakidis Z, Mant C, Cason J. Bridging the Financial Gap Through Providing Contract Services: A Model for Publicly Funded Clinical Biobanks. Biopreserv Biobank 2012; 10:357-60. [DOI: 10.1089/bio.2012.0009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Zisis Kozlakidis
- Department of Infectious Diseases, King's College London, Guy's Hospital, London, United Kingdom
- The King's College London Infectious Diseases BioBank, The National Institute of Health Research's Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
| | - Christine Mant
- Department of Infectious Diseases, King's College London, Guy's Hospital, London, United Kingdom
| | - John Cason
- Department of Infectious Diseases, King's College London, Guy's Hospital, London, United Kingdom
- The King's College London Infectious Diseases BioBank, The National Institute of Health Research's Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
| |
Collapse
|